ASH News Daily 2013 - Day 3 - (Page A-1)
Read this issue online at
www.hematology.org/ashnewsdaily2013_monday
Follow us on Twitter using #ASH13
SCHEDULE
9:00 - 10:00 a.m.
E. Donnall Thomas Lecture
Title: Sailing to Ithaka: Gene Therapy's
Odyssey from Investigational Agent to
Therapeutic Product
Speaker: Katherine A. High, MD
Hall F, Convention Center
10:30 a.m. - 12:00 noon
Spotlight Sessions
(ticketed sessions)
Various locations in the convention
center
12:15 - 1:15 p.m.
ASH Choosing Wisely®
List
Room 243-245, Convention Center
12:15 - 1:15 p.m.
Featured Topic: Chimeric Antigen
Receptors (CAR): Driving
Immunotherapy!
Room E3, Convention Center
1:30 - 2:30 p.m.
Ernest Beutler Lecture and Prize
Title: Thrombopoietin: From
Molecule to Medicine
Speakers: Kenneth Kaushansky, MD,
and David J. Kuter, MD, DPhil
Hall F, Convention Center
2:45 - 4:15 p.m.
Spotlight Sessions
(ticketed sessions)
Various locations in the convention
center
6:00 - 8:00 p.m.
Poster Hall Reception
Hall E & G, Convention Center
Chemoimmunotherapy: The Key to
Open the Door for Elderly CLL Patients
Plus Chlorambucil (Clb) Versus
Rituximab Plus Clb in Patients
with Chronic Lymphocytic Leukemia
(CLL) and Co-Existing Medical
BY ANITA RAJASEKHAR, MD, MS, AND
MARC ZUMBERG, MD
T
he treatment of elderly patients
with chronic lymphocytic
leukemia (CLL) is an
important topic of investigation
given that the median age of newly
diagnosed CLL patients is 72 years.
Elderly patients are often excluded
from clinical trials due to comorbidities
that compromise their ability
to tolerate aggressive treatments.
For frail, elderly patients with CLL
who are unable to tolerate intense
therapies, no currently available
therapies are superior to standard
chlorambucil (Clb) monotherapy.
However, the closed door to this
unmet treatment need may now
be unlocked by the novel glycoengineered
type II CD20 antibody,
obinutuzumab (GA101). In the Plenary
abstract, "Head-to-Head Comparison
of Obinutuzumab (GA101)
BY CAROLINE CROMWELL, MD
adequate and appropriate blood
cell production to be continued
over a lifetime. This system of
checks and balances must run like
a well-oiled machine. Many of the
parts that keep this machine running
remain a mystery. Overall, the
stem cell population is maintained
at a steady state. Somatic cells must
be able to self-renew as well as to
W
IN THIS SECTION
B-Cell Lymphoma
A-2
Program Updates
A-4
Beutler Lecture
A-5
Sports Medicine
A-6
Sickle Cell Disease
A-16
Don't miss the Featured
Topic: Chimeric Antigen Receptors
(CAR): Driving Immunotherapy!
Session today
at 12:15 p.m. in E3 (located
inside Hall E) in the convention
center.
ithin the bone marrow,
a fine balance must be
maintained in order for
Conditions (Comorbidities): Final
Stage 2 Results of the CLL11 Trial,"
»» CLL Page A-16
ASH President Dr. Janis Abkowitz provides an overview of Sunday's
Plenary Scientific Session.
Keeping "Mom" Well Behaved
differentiate. Cells must also have
cues to remain at rest, or quiescent.
Otherwise uncontrolled growth can
occur. Within the bone marrow regulation
of the stem cell pool occurs
through the existence of microenvi-
roments or niches.
In yesterday's Plenary Scientific
presentation titled "Megakaryocytes
Regulate Hematopoietic Stem
»» STEM CELLS Page A-17
Sue Van,
President of
the Wallace
H. Coulter
Foundation,
presents ASH
President
Dr. Janis L.
Abkowitz a
check for $5
million. This
endowment
will provide
funding to
enable ASH
to continue
to develop
innovative
programs
that continue
Coulter's
legacy.
http://www.hematology.org/ashnewsdaily2013_monday
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3
Table of Contents
ASH News Daily 2013 - Day 3
https://www.nxtbookmedia.com